163 related articles for article (PubMed ID: 31760599)
1. IDegLira Improves Glycemic Control in Japanese Patients with Uncontrolled Type 2 Diabetes on Premixed Insulin Therapy.
Watada H; Ross Agner BF; Doshi A; Bardtrum L; Ranthe MF; Billings LK
Diabetes Ther; 2020 Jan; 11(1):331-339. PubMed ID: 31760599
[TBL] [Abstract][Full Text] [Related]
2. Superior HbA1c control with the fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with a maximum dose of 50 units of insulin degludec in Japanese individuals with type 2 diabetes in a phase 3, double-blind, randomized trial.
Watada H; Kaneko S; Komatsu M; Agner BR; Nishida T; Ranthe M; Nakamura J
Diabetes Obes Metab; 2019 Dec; 21(12):2694-2703. PubMed ID: 31423685
[TBL] [Abstract][Full Text] [Related]
3. The Benefit of Insulin Degludec/Liraglutide (IDegLira) Compared With Basal-Bolus Insulin Therapy is Consistent Across Participant Subgroups With Type 2 Diabetes in the DUAL VII Randomized Trial.
Billings LK; Agner BFR; Altuntas Y; Grøn R; Halladin N; Klonoff DC; Tentolouris N; Jódar E
J Diabetes Sci Technol; 2021 May; 15(3):636-645. PubMed ID: 32107930
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of IDegLira in Participants with Type 2 Diabetes in India Uncontrolled on Oral Antidiabetic Drugs and Basal Insulin: Data from the DUAL Clinical Trial Program.
Khunti K; Mohan V; Jain SM; Boesgaard TW; Begtrup K; Sethi B
Diabetes Ther; 2017 Jun; 8(3):673-682. PubMed ID: 28332144
[TBL] [Abstract][Full Text] [Related]
5. Benefits of insulin degludec/liraglutide are maintained even in patients discontinuing sulphonylureas or dipeptidyl peptidase-4 inhibitors upon initiation of degludec/liraglutide therapy: A post hoc analysis of the DUAL II and DUAL IX trials.
Janez A; Őrsy P; Stachlewska K; Salvesen-Sykes K; Billings LK; Philis-Tsimikas A
Diabetes Obes Metab; 2020 Apr; 22(4):658-668. PubMed ID: 31858673
[TBL] [Abstract][Full Text] [Related]
6. DUAL II China: Superior HbA1c reductions and weight loss with insulin degludec/liraglutide (IDegLira) versus insulin degludec in a randomized trial of Chinese people with type 2 diabetes inadequately controlled on basal insulin.
Pei Y; Agner BR; Luo B; Dong X; Li D; Liu J; Liu L; Liu M; Lu Y; Nishida T; Xu X; Mu Y
Diabetes Obes Metab; 2021 Dec; 23(12):2687-2696. PubMed ID: 34387411
[TBL] [Abstract][Full Text] [Related]
7. DUAL I China: Improved glycemic control with IDegLira versus its individual components in a randomized trial with Chinese participants with type 2 diabetes uncontrolled on oral antidiabetic drugs.
Wang W; Agner BFR; Luo B; Liu L; Liu M; Peng Y; Qu S; Stachlewska KA; Wang G; Yuan G; Zhang Q; Ning G
J Diabetes; 2022 Jun; 14(6):401-413. PubMed ID: 35762390
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of the fixed-ratio combination of insulin degludec and liraglutide by baseline glycated hemoglobin, body mass index and age in Japanese individuals with type 2 diabetes: A subgroup analysis of two phase III trials.
Komatsu M; Watada H; Kaneko S; Ross Agner BF; Nishida T; Kaku K
J Diabetes Investig; 2021 Sep; 12(9):1610-1618. PubMed ID: 33595901
[TBL] [Abstract][Full Text] [Related]
9. IDegLira improves patient-reported outcomes while using a simple regimen with fewer injections and dose adjustments compared with basal-bolus therapy.
Miller E; Doshi A; Grøn R; Jódar E; Őrsy P; Ranthe MF; Sugimoto D; Tentolouris N; Viljoen A; Billings LK
Diabetes Obes Metab; 2019 Dec; 21(12):2643-2650. PubMed ID: 31385425
[TBL] [Abstract][Full Text] [Related]
10. IDegLira Improves Both Fasting and Postprandial Glucose Control as Demonstrated Using Continuous Glucose Monitoring and a Standardized Meal Test.
Holst JJ; Buse JB; Rodbard HW; Linjawi S; Woo VC; Boesgaard TW; Kvist K; Gough SC
J Diabetes Sci Technol; 2015 Oct; 10(2):389-97. PubMed ID: 26443290
[TBL] [Abstract][Full Text] [Related]
11. Switching from Multiple Insulin Injections to a Fixed Combination of Degludec and Liraglutide in Patients with Type 2 Diabetes Mellitus: Results from the Simplify Study After 6 Months.
Martinka E; Dravecká I; Tkáč I
Diabetes Ther; 2023 Sep; 14(9):1503-1515. PubMed ID: 37402960
[TBL] [Abstract][Full Text] [Related]
12. A Randomized Controlled Trial Comparing the Efficacy and Safety of IDegLira Versus Basal-Bolus in Patients With Poorly Controlled Type 2 Diabetes and Very High HbA1c ≥9-15%: DUAL HIGH Trial.
Galindo RJ; Moazzami B; Scioscia MF; Zambrano C; Albury BS; Saling J; Vellanki P; Pasquel FJ; Davis GM; Fayfman M; Peng L; Umpierrez GE
Diabetes Care; 2023 Sep; 46(9):1640-1645. PubMed ID: 37459574
[TBL] [Abstract][Full Text] [Related]
13. Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial.
Aroda VR; González-Galvez G; Grøn R; Halladin N; Haluzík M; Jermendy G; Kok A; Őrsy P; Sabbah M; Sesti G; Silver R
Lancet Diabetes Endocrinol; 2019 Aug; 7(8):596-605. PubMed ID: 31189519
[TBL] [Abstract][Full Text] [Related]
14. The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial.
Linjawi S; Bode BW; Chaykin LB; Courrèges JP; Handelsman Y; Lehmann LM; Mishra A; Simpson RW
Diabetes Ther; 2017 Feb; 8(1):101-114. PubMed ID: 27943107
[TBL] [Abstract][Full Text] [Related]
15. Modeling the Long-Term Cost-Effectiveness of IDegLira in Patients with Type 2 Diabetes Who are Failing To Meet Glycemic Targets on Basal Insulin Alone in The Netherlands.
Hunt B; Glah D; van der Vliet M
Diabetes Ther; 2017 Aug; 8(4):753-765. PubMed ID: 28523483
[TBL] [Abstract][Full Text] [Related]
16. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison.
Ilag LL; Kerr L; Malone JK; Tan MH
Clin Ther; 2007; 29 Spec No():1254-70. PubMed ID: 18046926
[TBL] [Abstract][Full Text] [Related]
17. A Fixed Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) Reduces Glycemic Fluctuation and Brings More Patients with Type 2 Diabetes Within Blood Glucose Target Ranges.
King AB; Philis-Tsimikas A; Kilpatrick ES; Langbakke IH; Begtrup K; Vilsbøll T
Diabetes Technol Ther; 2017 Apr; 19(4):255-264. PubMed ID: 28282219
[TBL] [Abstract][Full Text] [Related]
18. Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 Diabetes.
Harris S; Abrahamson MJ; Ceriello A; Charpentier G; Evans M; Lehmann R; Liebl A; Linjawi S; Holt RIG; Hosszúfalusi N; Rutten G; Vilsbøll T
Drugs; 2020 Feb; 80(2):147-165. PubMed ID: 31960258
[TBL] [Abstract][Full Text] [Related]
19. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira).
Buse JB; Vilsbøll T; Thurman J; Blevins TC; Langbakke IH; Bøttcher SG; Rodbard HW;
Diabetes Care; 2014 Nov; 37(11):2926-33. PubMed ID: 25114296
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of insulin degludec/liraglutide versus insulin degludec/insulin aspart in Japanese patients with type 2 diabetes.
Oya J; Nakagami T; Hasegawa Y; Kondo Y; Katamine A; Shimizu M; Kubota R; Suda R; Babazono T
Diabetol Int; 2024 Apr; 15(2):237-243. PubMed ID: 38524940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
